{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:35:44Z","timestamp":1791516944565,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtct.2023.01.021","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T18:14:30Z","timestamp":1674756870000},"page":"228-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80\/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies"],"prefix":"10.1016","volume":"29","author":[{"given":"Sarah","family":"Nikiforow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-3200","authenticated-orcid":false,"given":"Rebecca A.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis Irene","family":"Warkentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Lynn","family":"Aho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey L.","family":"Hlucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Habucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mecide","family":"Gharibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.01.021_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-017-0265-y","article-title":"Moffitt Immunotherapy Working Group, Immune Cell Therapy (ICE-T) Program. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap","volume":"5","author":"Locke","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.01.021_bib0002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtct.2022.05.043","article-title":"ASTCT Committee on Practice Guidelines survey on evaluation & management of diffuse large B-cell lymphoma after failure of chimeric antigen receptor T cell therapy (CAR-T) therapy","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.01.021_bib0003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.01.021_bib0004","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","volume":"56","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.021_bib0005","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.021_bib0006","doi-asserted-by":"crossref","unstructured":"US Food and Drug Administration. Abecma (idecabtagene vicleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel. Published 2021. Updated April 21, 2021. Accessed August 18, 2022.","DOI":"10.1097\/01.COT.0000753336.18581.7d"},{"key":"10.1016\/j.jtct.2023.01.021_bib0007","unstructured":"US Food and Drug Administration. Kymriah (tisagenlecleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Published 2022. Updated July 7, 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0008","unstructured":"US Food and Drug Administration. Yescarta (axicabtagene ciloleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel. Published 2022. Updated April 14, 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0009","unstructured":"US Food and Drug Administration. Breyanzi (lisocabtagene maraleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel. Published 2022. Updated July 1, 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0010","unstructured":"US Food and Drug Administration. Tecartus (brexucabtagene autoleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel. Published 2022. Updated April 13, 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0011","unstructured":"US Food and Drug Administration. Carvykti (ciltacabtagene autoleucel). Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/carvykti. Published 2022. Updated March 21, 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0012","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.021_bib0013","unstructured":"Alliance for Regenerative Medicine. Regenerative medicine in 2021: a year of firsts and records. Available at: http:\/\/alliancerm.org\/wp-content\/uploads\/2021\/08\/ARM-H1-2021-Report.pdf. Published 2021. Accessed May 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0014","unstructured":"US Food and Drug Administration. Approved cellular and gene therapy products. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Published 2022. Updated August 17, 2022. Accessed August 17, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcyt.2021.09.009","article-title":"ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products","volume":"24","author":"Bersenev","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2023.01.021_bib0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcyt.2021.09.010","article-title":"Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience","volume":"24","author":"Hanley","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2023.01.021_bib0018","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.021_bib0019","unstructured":"Association for the Advancement of Blood & Biotherapies. AABB standards & accreditation. Available at: https:\/\/www.aabb.org\/standards-accreditation. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0020","unstructured":"National Marrow Donor Program\/Be The Match. NMDP Standards. Available at: https:\/\/network.bethematchclinical.org\/transplant-centers\/nmdp-standards\/. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0021","unstructured":"Foundation for the Accreditation of Cellular Therapies. About FACT. Available at: https:\/\/www.factglobal.org\/about\/. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0022","unstructured":"American Society for Transplantation and Cellular Therapy. About ASTCT. Available at: https:\/\/www.astct.org\/about\/about-astct. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0023","unstructured":"International Society for Cell & Gene Therapy. About ISCT. Available at: https:\/\/www.isctglobal.org\/about\/about-us. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0024","unstructured":"European Society for Blood and Marrow Transplantation. JACIE Accreditation. Available at: https:\/\/www.ebmt.org\/jacie-accreditation. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0025","unstructured":"Center for International Blood and Marrow Transplant Research. CIBMTR: Who we are. Available at: https:\/\/www.cibmtr.org\/About\/WhoWeAre\/pages\/index.aspx. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0026","unstructured":"CIBMTR. 2021 Annual Report. Available at: https:\/\/www.cibmtr.org\/About\/AdminReports\/Documents\/2021%20Annual%20Report%20FINAL.pdf. Published 2022. Accessed February 3, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0027","unstructured":"CIBMTR. CIBMTR slides and reports. Available at: https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary-Slides-Reports. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0028","unstructured":"Standards Coordinating Body The Standards Coordinating Body for Regenerative Medicine. Available at: https:\/\/www.standardscoordinatingbody.org\/. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0029","unstructured":"Parenteral Drug Association. About PDA. Available at: https:\/\/www.pda.org\/about-pda. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0030","unstructured":"International Council for Commonality in Blood Banking Automation (ICCBBA). What is ISBT 128? . Available at: https:\/\/www.isbt128.org\/. Published 2021. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0031","unstructured":"ICCBBA. Who uses ISBT 128? Available at: https:\/\/www.isbt128.org\/isbt-128-basics. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0032","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12967-022-03385-9","article-title":"The need for uniform and coordinated practices involving centrally manufactured cell therapies","volume":"20","author":"Stroncek","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtct.2023.01.021_bib0033","unstructured":"Be The Match BioTherapies. Quality system audit program. Available at: https:\/\/bethematchbiotherapies.com\/solutions\/quality-system-audit-program\/. Published 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0034","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.01.021_bib0035","unstructured":"National Comprehensive Cancer Network (NCCN). Management of immunotherapy-related toxicities. Available at: www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Version: 1.2022. Accessed November 1, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0036","unstructured":"Society for Immunotherapy of Cancer. SITC certificate in cancer immunotherapy. Available at: https:\/\/www.sitcancer.org\/professional-development\/certificate. Accessed XXX."},{"key":"10.1016\/j.jtct.2023.01.021_bib0037","unstructured":"US Food and Drug Administration. Risk evaluation and mitigation strategies (REMS). Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm. Accessed November 1, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0038","unstructured":"Health Resources and Services Administration. Legislation. Available at: https:\/\/bloodstemcell.hrsa.gov\/about\/legislation. Published 2022. Updated April 2022. Accessed August 18, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0039","unstructured":"EBMT. The draft ISBT 128 standard chain of identity (CoI) identifier is open for public comment. Available at: https:\/\/www.ebmt.org\/ebmt\/news\/draft-isbt-128-standard-chain-identity-coi-identifier-open-public-comment. Published 2022. Accessed August 29, 2022."},{"key":"10.1016\/j.jtct.2023.01.021_bib0040","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/bloodadvances.2021004604","article-title":"Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers","volume":"5","author":"Paczesny","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.01.021_bib0041","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtct.2022.09.020","article-title":"The ASTCT-NMDP ACCESS Initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem","volume":"28","author":"Auletta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.01.021_bib0042","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/CCO.0000000000000665","article-title":"Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life","volume":"32","author":"McGrath","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jtct.2023.01.021_bib0043","unstructured":"American Society for Transplantation and Cellular Therapy. 2021AcCELLerate forum: creating a sustainable ecosystem of cell and gene therapy [virtual]. November 18-19, 2021."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723000453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723000453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:20:23Z","timestamp":1721668823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723000453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2666636723000453"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.01.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80\/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}